Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01173549 · ClinicalTrials.gov registry record · Phase 1
A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers
A Phase 1 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01173549 is a Phase 1 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 26 participants.
The verdict
NCT01173549, a Phase 1 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of canagliflozin on gastrointestinal glucose absorption in healthy volunteers.
Interventions
- OTHER no intervention
- DRUG Canagliflozin/Placebo Placebo/Canagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01173549
The ClinicalTrials.gov registry entry for NCT01173549 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which no intervention is the first listed.
NCT01173549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01173549 about?
NCT01173549 is a clinical study titled "A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers". The purpose of this study is to evaluate the effect of canagliflozin on gastrointestinal glucose absorption in healthy volunteers.
What is the current status of trial NCT01173549?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2010-11. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01173549?
The interventions under investigation include: no intervention (OTHER), Canagliflozin/Placebo Placebo/Canagliflozin (DRUG).
Who is sponsoring clinical trial NCT01173549?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.